| abstract |
Disclosed are surprising new methods and kits for identifying and treating cancer patients treatable with PS-targeting antibodies, particularly for identifying and treating cancer patients using bavituximab and combination therapy with bavituximab. The present methods and kits suggest that pre-treatment blood levels of β2-glycoprotein 1 (β2GPI), particularly functional β2GPI, in a defined range serve as an accurate predictor of patients with better therapeutic outcome. Based on surprising findings. [Selection diagram] FIG. |